Aditxt

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Aston Martin (AML) near 38p: Can stronger Valhalla sales overcome £1.57bn debt and justify its valuation?

Arbor Realty Trust (ABR) suspends dividend as $1.25bn in troubled assets sends stock down 29%

A representative image of a nuclear power plant highlighting the global focus on lifetime extensions as a strategy to close the energy gap before next-generation reactors are deployed.

Constellation secures conditional $5bn US loan commitment for nuclear power expansion

Scotiabank completes C$600m Scotia Group Jamaica minority buyout

Representative image: Aditxt’s pivot into precision oncology, diagnostics, retail-stock catalysts, and digital-asset strategy highlights the high-risk reinvention story now drawing attention around ADTX shares.

Aditxt eyes Pearsanta IPO and oncology pivot as ADTX (NASDAQ) tests retail patience

Aditxt regained Nasdaq compliance, then filed to issue 148 million shares. ADTX retail investors are watching Pearsanta's IPO and a bitXbio crypto pivot.

μFR system
αvβ6-integrin
α4β7 integrin
Þorgerður Katrín Gunnarsdóttir
Zywie Ventures
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynyz
ZYNRELEF

May 2, 2026